Canaccord raised the firm’s price target on Verve Therapeutics (VERV) to $32 from $29 and keeps a Buy rating on the shares. The firm said its 3Q24 earnings report was positive, with notable clinical progress made in both base editing programs.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV: